

# Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Breast Cancer

Ca-A Cancer Journal for Clinicians

55, 145-163

DOI: [10.3322/canjclin.55.3.145](https://doi.org/10.3322/canjclin.55.3.145)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Exemestane. American Journal of Cancer, 2006, 5, 259-272.	0.4	5
2	Chemoprevention of breast cancer. Lancet, The, 2006, 367, 1382-1383.	6.3	9
3	Adjuvant trials: Aromatase inhibitors in early breast cancer – Are they alike?. Cancer Treatment Reviews, 2006, 32, 532-540.	3.4	2
4	Hormonal breast cancer agents: Implications for the primary care provider. Journal of the American Academy of Nurse Practitioners, 2006, 18, 518-523.	1.4	3
5	The extended adjuvant NCIC CTG MA.17 trials: Initial and rerandomization studies. Breast, 2006, 15, 14-20.	0.9	8
6	Inhibidores de la aromatasa y osteoporosis. Revista Española De Enfermedades Metabólicas y Endocrinas, 2006, 15, 55-56.	0.0	1
7	Update on COX-2 inhibitor patents with a focus on optimised formulation and therapeutic scope of drug combinations making use of COX-2 inhibitors. Expert Opinion on Therapeutic Patents, 2006, 16, 403-430.	2.4	7
8	The Influence of Endocrine Effects of Adjuvant Therapy on Quality of Life Outcomes in Younger Breast Cancer Survivors. Oncologist, 2006, 11, 96-110.	1.9	129
9	New agents in development for breast cancer. Current Opinion in Obstetrics and Gynecology, 2007, 19, 68-74.	0.9	7
10	Advances in Hormonal Therapy for Breast Cancer. Seminars in Oncology Nursing, 2007, 23, 46-54.	0.7	27
12	Aromatase Inhibitors in Early Hormone Receptor-Positive Breast Cancer. Drugs, 2008, 68, 1-15.	4.9	5
13	The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Annals of Oncology, 2008, 19, 16-27.	0.6	60
14	CYP1B1 Is Not a Major Determinant of the Disposition of Aromatase Inhibitors in Epithelial Cells of Invasive Ductal Carcinoma. Drug Metabolism and Disposition, 2008, 36, 963-970.	1.7	6
15	Growth Factor Receptors and Apoptosis Regulators: Signaling Pathways, Prognosis, Chemosensitivity and Treatment Outcomes of Breast Cancer. Breast Cancer: Basic and Clinical Research, 2009, 3, BCBCR.S2492.	0.6	13
16	Dietary administration of the licorice flavonoid isoliquiritigenin deters the growth of MCF-7 cells overexpressing aromatase. International Journal of Cancer, 2009, 124, 1028-1036.	2.3	56
17	Systemic Metabolic Radiopharmaceutical Therapy in the Treatment of Metastatic Bone Pain. Seminars in Nuclear Medicine, 2010, 40, 89-104.	2.5	137
18	Molecular therapy of breast cancer: progress and future directions. Nature Reviews Endocrinology, 2010, 6, 485-493.	4.3	104
19	Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7. Molecular and Cellular Endocrinology, 2011, 344, 51-58.	1.6	48

#	ARTICLE	IF	CITATIONS
20	Internal radiotherapy of painful bone metastases. <i>Methods</i> , 2011, 55, 258-270.	1.9	27
21	The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice. <i>Journal of Nutritional Biochemistry</i> , 2012, 23, 1230-1237.	1.9	56
22	Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 385-395.	1.1	37
23	Breast cancer in the elderly—Should it be treated differently?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, 26-33.	0.3	62
24	The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1112-1116.	1.9	22
25	Radionuclide Therapy of Painful Bone Metastases—A Comparative Study Between Consecutive Radionuclide Infusions, Combination With Chemotherapy, and Radionuclide Infusions Alone. <i>American Journal of Hospice and Palliative Medicine</i> , 2013, 30, 745-751.	0.8	11
26	Screening of aromatase inhibitors in traditional Chinese medicines by electrophoretically mediated microanalysis in a partially filled capillary. <i>Journal of Separation Science</i> , 2013, 36, 2691-2697.	1.3	24
27	Synergistic anticancer effects of a bioactive subfraction of <i>Strobilanthes crispus</i> and tamoxifen on MCF-7 and MDA-MB-231 human breast cancer cell lines. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 252.	3.7	36
28	Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 2721.	1.0	6
29	The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. <i>Nutrients</i> , 2016, 8, 581.	1.7	118
31	Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment. <i>Cancer Biomarkers</i> , 2017, 18, 183-190.	0.8	3
32	Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer. <i>BioMed Research International</i> , 2018, 2018, 1-12.	0.9	12
33	Single Nucleotide Polymorphisms in 25-Hydroxyvitamin D3 1-Alpha-Hydroxylase (CYP27B1) Gene: The Risk of Malignant Tumors and Other Chronic Diseases. <i>Nutrients</i> , 2020, 12, 801.	1.7	16
34	Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113037.	2.6	33
35	<sup>188</sup> Re-HEDP therapy in the therapy of painful bone metastases. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 133.	0.3	9
36	Targeting Aromatase and Estrogen Signaling for Breast Cancer. <i>Journal of Nanomedicine &amp; Biotherapeutic Discovery</i> , 2014, 04, .	0.6	0